Romosozumab Improves Bone Strength in Women With T2D

TOPLINE: Romosozumab for 12 months followed by alendronate for 24 months leads to greater improvements in lumbar spine bone density and trabecular bone scores than alendronate alone for 36 months in postmenopausal women with type 2 diabetes (T2D) and osteoporosis. METHODOLOGY: Lower trabecular bone scores, which are associated with increased fracture risk…
Read More